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A genome-engineered bioartificial implant 
for autoregulated anticytokine drug delivery
Yun-Rak Choi1,2,3,4†, Kelsey H. Collins1,2,3†, Luke E. Springer5, Lara Pferdehirt1,2,3,6,  
Alison K. Ross1,2,3,6, Chia-Lung Wu1,2,3‡, Franklin T. Moutos7, Natalia S. Harasymowicz1,2,3, 
Jonathan M. Brunger8,9, Christine T. N. Pham5, Farshid Guilak1,2,3,6,7*
Biologic drug therapies are increasingly used for inflammatory diseases such as rheumatoid arthritis but may cause 
significant adverse effects when delivered continuously at high doses. We used CRISPR-Cas9 genome editing of 
iPSCs to create a synthetic gene circuit that senses changing levels of endogenous inflammatory cytokines to trigger a 
proportional therapeutic response. Cells were engineered into cartilaginous constructs that showed rapid activation 
and recovery in response to inflammation in vitro or in vivo. In the murine K/BxN model of inflammatory arthritis, 
bioengineered implants significantly mitigated disease severity as measured by joint pain, structural damage, 
and systemic and local inflammation. Therapeutic implants completely prevented increased pain sensitivity and 
bone erosions, a feat not achievable by current clinically available disease-modifying drugs. Combination tissue 
engineering and synthetic biology promises a range of potential applications for treating chronic diseases via 
custom-designed cells that express therapeutic transgenes in response to dynamically changing biological signals.
INTRODUCTION
Disease-modifying antirheumatic biologic drugs have revolutionized 
the treatment of autoimmune diseases; however, approximately 40% 
of patients with rheumatoid arthritis (RA) fail to respond to treat-
ment (1). Moreover, antirheumatic biologic drugs suppress the immune 
system, predisposing patients to substantial adverse effects (AEs), such 
as increased risk of infection (2). Biologic drugs are generally designed 
to target several inflammatory cytokines and pathways, including 
interleukin-1 (IL-1), IL-6, and tumor necrosis factor– (TNF-). While 
the severity of RA fluctuates over time, these drugs are administered 
continuously at high concentrations, regardless of endogenous cy-
tokine levels or the kinetics of RA symptoms. The development of 
specific therapeutic strategies that can sense and respond to endogenous 
levels of inflammatory mediators could overcome some of the chal-
lenges observed with constant delivery of cytokine inhibitors and 
mitigate unwanted AEs (3–6).
Here, we used CRISPR-Cas9 genome engineering (7, 8) to create 
such a self-regulating synthetic gene circuit in induced pluripotent 
stem cells (iPSCs). These cells were engineered into a bioartificial im-
plant and evaluated in vitro and in vivo for their ability to produce 
anticytokine biologic drugs in response to inflammatory signals such 
as IL-1 or TNF- by transcribing their biologic inhibitors in a feedback- 
controlled manner (3), driven by the promoter of chemokine (C-C) 
motif ligand 2 (Ccl2) (9). For proof of concept as a disease therapy, 
we delivered the bioengineered implants in the murine model of 
K/BxN inflammatory arthritis, which has been shown to be critically 
dependent on IL-1 (10). Although IL-1 receptor antagonist (IL-1Ra) 
has been shown to mitigate disease in animal models of RA and slows 
joint damage (assessed radiographically) in humans (11), it is not 
routinely used as a disease-modifying biologic in RA because of its 
short half-life and modest effects (12). We posit that delivering IL-1Ra 
using a system that can sense and respond to dynamically changing 
levels of endogenous inflammatory mediators may improve efficacy 
while mitigating the side effects of continuous biologic delivery.
Our results show that dynamic, autoregulated delivery of IL-1Ra 
mitigated inflammation, pain, and structural damage in K/BxN 
arthritis that was superior to conventional disease-modifying anti-
rheumatic drugs (DMARDs) in this context. This therapeutic approach 
completely abrogated bone erosions as compared to conventional 
disease-modifying drugs and biologics, which is yet to be achieved 
by daily subcutaneous injection of IL-1Ra (anakinra). Furthermore, 
these therapeutic constructs could be reactivated repeatedly, following 
in vivo inflammatory triggers (such as RA flares), a clinically im-
portant facet of this approach that has relevant translational impact 
for long-term drug delivery using this approach.
RESULTS
Cell-based injection of genome-engineered iPSCs sense 
and respond to inflammation in vivo
Using CRISPR-Cas9 genome engineering, iPSCs were edited to in-
sert either the gene for IL-1Ra (Il1rn) or luciferase (Luc) at the Ccl2 
locus, creating a self-regulating gene circuit that transcribes Il1rn 
or Luc in response to inflammatory activation of Ccl2 (referred as 
Ccl2-IL1Ra or Ccl2-Luc cells; Fig. 1) (3). We initially examined the 
therapeutic potential of Ccl2-Luc cells (13) by intraperitoneal injec-
tion into the K/BxN murine model of arthritis (10). This model has 
a well-characterized IL-1–dependent development of spontaneous 
arthritis in the F1 generation that is observed starting from 3 to 4 weeks 
and progressing to advanced disease at 7 to 8 weeks of age (14). 
When Ccl2-Luc cells were delivered via intraperitoneal injection to 
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mice 4 and 8 weeks of age, we detected luciferase signal at 1 hour 
after implantation that persisted over 24  hours of monitoring 
(Fig. 2A). Older K/BxN F1 mice demonstrated increased lumines-
cence intensity compared to the younger mice, concordant with the 
increased clinical score observed in 8-week-old versus 4-week-old 
mice (Fig. 2, B and C). Luminescence intensity observed at 24 hours 
after injection demonstrated a strong positive relationship with 
clinical scores across all animals (Spearman’s r = 0.93, P = 0.033), 
indicating that these cells can sense and proportionately respond to 
their environment and can provide a real-time luminescence read-
out of systemic inflammation.
Next, Ccl2-Luc (controls) and Ccl2-IL1Ra cells were delivered 
intraperitoneally and tested in the context of K/BxN serum transfer 
arthritis (STA) (15), a transient arthritis that persists for 7 to 14 days 
in wild-type mice. Intraperitoneally injected bioengineered cells were 
no longer detectable 24 hours after injection. While the control 
Ccl2-Luc cells did not have an effect on K/BxN STA (Fig. 2D), Ccl2- 
IL1Ra cell delivery resulted in small but significant and sustained 
improvement in ankle thickness, tactile allodynia, and pressure-pain 
hyperalgesia at the ankle, despite being cleared 24 hours after injection. 
Intraperitoneally injected Ccl2-IL1Ra cells, however, did not miti-
gate clinical scores (P = 0.10; Fig. 2E).
Tissue-engineered bioartificial implants sense and respond 
to inflammation in a feedback-controlled manner
To create a stable cell-based implant, Ccl2–IL-1Ra and Ccl2-Luc cells 
were seeded onto three-dimensional (3D) woven poly(-caprolactone) 
(PCL) scaffolds (Fig. 3A) (16) and chondrogenically differentiated (17) 
over 21 days into chondrocyte-like cells that produced a proteoglycan-rich 
matrix (Fig. 3, B to D). This approach was used because chondrocyte-like 
cells within a cartilage matrix exhibit minimal migration and re-
quire neither vasculature nor innervation for long-term survival, 
relying on diffusion for nutrient transport even under physiolog-
ically relevant hypoxic conditions (18–21). In culture, the Ccl2-IL-
1Ra bioartificial implants rapidly sensed and responded to IL-1 
stimulation by producing IL-1Ra (Fig. 3E) in a feedback-controlled 
manner (Fig. 3, F and G). A second set of cells were similarly engi-
neered to produce soluble TNF receptor 1 (sTNFR1), and implants 
created from Ccl2-sTNFR1 cells behaved similarly in vitro (fig. S1). 
The cell-secreted anticytokine biologics suppressed the response to 
IL-1 or TNF- stimulation, reducing mRNA levels for proinflam-
matory mediators Il6 and Ccl2, and for matrix metalloproteinases, 
Mmp9 and Mmp13 (Fig. 3, H to K, and fig. S1), as compared to the 
control Ccl2-Luc construct.
Bioartificial implants demonstrate stability as a long-term drug 
delivery system and demonstrate retriggering dynamics in vivo
These bioartificial constructs were implanted subcutaneously in K/BxN 
transgenic F1 mice, which develop spontaneous arthritis, and mice 
with K/BxN STA (15). Ccl2-Luc constructs exhibited high luminescence 
relative to background levels, indicating responsiveness of the con-
structs in vivo, and cell survival in a chronic inflammatory environment 
up to 5 weeks after implantation in F1 K/BxN mice (Fig. 4, A and B). 
In the K/BxN STA model, Ccl2-Luc constructs exhibited similar lumi-
nescence signals for at least 7 days when they were implanted sub-
cutaneously near the knee or on the dorsum of mice (Fig. 4C). 
Explanted Ccl2-Luc constructs from F1 K/BxN mice at 5 weeks also 
confirmed high cell viability (~70% on average) for both Ccl2-IL1Ra 
and Ccl2-sTNFR1 constructs, via live/dead staining by confocal 
microscopy (Fig. 4D).
We then determined the activation and reactivation dynamics of 
this genetically engineered drug delivery platform. First, we implanted 
Ccl2-Luc constructs into mice and challenged them 7 days later with 
K/BxN serum administration to induce STA (Fig. 4E). Significant in-
creases in luminescence were detected as early as 1 hour after chal-
lenge with K/BxN serum in vivo (Fig. 4F). We observed that the photon 
flux measured by IVIS imaging was concordant with the clinical score, 
such that when the inflammatory arthritis flare waned at days 9 to 
14, the luminescence intensity also decreased, demonstrating in vivo 
on-off kinetics proportional to endogenous inflammatory signals 
(Fig. 4G). Furthermore, these constructs were able to be reactivated 
after a week-long washout period to similar photon flux levels ob-
served in response to the first K/BxN serum transfer. Ccl2-IL1Ra 
therapeutic implants maintained their efficacy after 30 days of dor-
mancy, exhibiting significant mitigation of clinical disease severity 
when rechallenged with K/BxN serum (Fig. 4, H and I). After 
implantation, Ccl2-Luc constructs maintained a fibrocartilaginous 
phenotype, illustrated by low Safranin O staining and robust Col II 
labeling using immunohistochemistry, and positive staining for Col I 
and Col X (Fig. 4J). The constructs exhibited increased cellularity 
[hematoxylin and eosin (H&E) staining] but did not show any 
vascularity, immune cell invasion, or calcification.
Bioartificial implants mitigate disease severity and pain 
in mice with inflammatory arthritis
To determine the ability of this self-regulating implant to mitigate 
arthritis in the STA model, constructs were implanted on the dorsal 
aspect of C57BL/6 mice (day −7) and allowed to recover before 
Fig. 1. Scaffold-mediated delivery of genome-engineered anticytokine cells. 
(A) CRISPR-Cas9 genome editing was used to engineer stem cells containing a synthetic 
gene circuit that expresses the IL-1Ra, an inhibitor of IL-1, in response to activation of 
the chemokine (C-C) motif ligand 2 (Ccl2) promoter. NF-B, nuclear factor B. (B) Cells 
were engineered to form stable cartilaginous constructs on three-dimensional (3D) 
woven scaffolds in chondrogenic media. Constructs were tested in vitro to assess 
on-off dynamics in response to changing levels of IL-1. (C) To test their efficacy, 
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intravenous K/BxN serum administration on day 0 (Fig. 5A). Ani-
mals receiving Ccl2-IL1Ra implants demonstrated significant ame-
lioration of arthritis severity, including 40% reductions in both 
clinical scores and ankle thickness, compared to control animals 
that received Ccl2-Luc constructs or no implant (Fig. 5, B and C).
Histologic analysis illustrated that animals with Ccl2-IL1Ra implants 
demonstrated significantly lower inflammation scores and had reduced 
cartilage degradation and proteoglycan loss (Fig. 5, D to F) when com-
pared to animals with Ccl2-Luc implants. Mice receiving Ccl2-IL1Ra 
constructs also exhibited significantly higher serum levels of IL-1Ra as 
compared to controls (Fig. 5, G to H). Serum IL-1Ra concentrations 
were correlated with clinical scores and ankle thickness (Fig. 5, I and J).
The reduction in disease severity in mice with Ccl2-IL1Ra con-
structs was also accompanied by a significant decrease in mechani-
cal pain sensitivity as measured by algometry and electronic Von 
Frey pain tests, whereas the control groups exhibited increased pain 
sensitivity (reduced pain thresholds) (Fig. 5, K and L). The pain threshold 
of each animal was also significantly correlated with serum levels of 
IL-1Ra (Fig. 5, M and N). Ccl2-sTNFR1 (fig. S3) or reduced dose of 
Ccl2-IL1Ra constructs (four scaffolds versus eight scaffolds; fig. S3) 
did not significantly mitigate K/BxN STA clinical severity, although 
both approaches significantly attenuated the increase in pain sensitivity 
(figs. S2 and 3). There was also evidence of a dose-dependent response 
in the clinical score and circulating levels for IL-1Ra with implantation 
of half the dose of Ccl2-IL1Ra constructs (four scaffolds; fig. S3). These 
data corroborate previous reports that TNF- and IL-1 signaling 
differentially affect inflammation and pain in K/BxN STA (10).
Bioartificial implants prevent bone and joint destruction 
in mice with K/BxN STA
Micro–computed tomography (microCT) of bone structure showed 
that mice receiving Ccl2-IL1Ra implants were completely protected 
from bone erosions that are characteristic of inflammatory arthritis. 
Treated mice had minimal or no bone erosions on day 7 following 
Fig. 2. Genome-edited cells were tested for therapeutic efficacy using an intraperitoneal injection. (A) Eight-week-old K/BxN F1 mice demonstrated increased lu-
ciferase signal over 24 hours, and (B) demonstrated increased disease burden compared to 4-week-old mice, (n = 3 to 4), (C) which had a significant positive association 
with luminescence intensity. (D) Rapid luciferase expression (within 1 hour) in response to supraphysiological levels of TNF- (left; right, no TNF- challenge). (E) Signifi-
cant mitigation of clinical scores was not observed (P = 0.10) with K/BxN STA after intraperitoneal injection of Ccl2-IL1Ra cells (F) but did significantly mitigate ankle 
thickness. Intraperitoneally injected Ccl2-IL1Ra cells also mitigated pain measured by (G) electronic Von Frey and (H) algometry in K/BxN STA mice. Values represent 
means ± SEM. Analysis: (A and E to H) Two-way repeated measures analysis of variance (ANOVA), after confirming normality, with a Geisser-Greenhouse correction. Exact 
P values are demonstrated for the main effect of group, except for when P < 0.001, as indicated. Interaction terms and time are demonstrated in the graphs. Not significant 
(NS), P > 0.05. Significant Sidak’s post hoc test per time point between groups with an italicized adjusted P value directly over each time point is shown. (B) Mann-Whitney 
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K/BxN serum transfer, whereas mice with Ccl2-Luc implants or no 
implant exhibited highly erosive disease as demonstrated by a high-
er ratio of bone surface to bone volume (BS/BV) and a lower ratio 
of bone volume per total volume (BV/TV) (Fig. 6, A to C). Histolog-
ic analysis was also concordant with the microCT observations for 
bone erosions (Fig. 6D). Ccl2-IL1Ra implants also showed protec-
tive effects on bone mineral density (BMD) (Fig. 6D). Quantitative 
measures of bony erosions (BS/BV) were negatively correlated with 
serum levels of IL-1Ra (Fig. 6E).
Mice that were treated with Ccl2-IL1Ra implants showed signif-
icant reductions in their inflammatory cytokine profiles as compared 
to control animals. Using a multiplexed cytokine assay, we observed 
significant reductions of serum levels for interferon- and IL-6 and an 
increase in serum levels for IL-10 in treated animals (Fig. 6, F to H). 
In the paw lysate of treated animals, we observed significant reduc-
tions in levels for IL-1, IL-6, Monocyte chemoattractant protein-1, 
keratinocytes-derived chemokine, also known as chemokine (C-X-C 
motif) ligand 1 (CXCL1), and TNF- in comparison to control animals 
(Fig. 6, I to M). There was a trend toward reduction in total level of 
IL-1 (IL-1 + IL-1) in animals that received Ccl2-IL1Ra implants 
compared to controls (P = 0.07; Fig. 6N).
Bioartificial implants demonstrate improved clinical efficacy 
to standard-of-care treatment
To benchmark this approach against several current DMARDs, 
we compared the clinical response of animals with K/BxN STA 
receiving Ccl2-IL1Ra implants to those treated with methotrexate, 
a conventional DMARD, or tofacitinib, a Janus kinase (JAK) in-
hibitor (22). We saw no significant mitigation of arthritis with 
methotrexate or JAK inhibitor (Fig. 7, A and B), while Ccl2-IL1Ra 
constructs mitigated ankle thickness (Fig. 7, C and D) and pre-
vented pressure-pain hyperalgesia (Fig. 7, E and F). Mice implanted 
with Ccl2-IL1Ra constructs maintained BV/TV (Fig. 7G) and had 
reduced bone erosions, operationalized by BS/BV (Fig. 7H), to 
levels of healthy paws. We also compared treatment with anakinra, 
a biologic drug inhibitor of IL-1, to cell-based delivery of IL-1Ra via 
Ccl2-IL1Ra implants (Fig. 7I). Despite exhibiting similar circulating 
levels of IL-1Ra, mice treated with a clinically relevant dose of 
anakinra did not show mitigation of arthritis, while mice that re-
ceived Ccl2-IL1Ra implants demonstrated improved disease scores 
6 days after K/BxN serum transfer (Fig. 7J). These data suggest 
that dynamic cell-based release of therapeutic levels of IL-1Ra on 
demand in response to endogenous inflammatory signals results in 
improved cytokine inhibition as compared to twice daily injections 
of anakinra.
DISCUSSION
In this study, we combined the principles of synthetic biology and 
tissue engineering to develop a genome-engineered implantable drug 
delivery system that can automatically sense and respond to inflam-
matory cytokines to produce therapeutic levels of anticytokine biologic 
Fig. 3. Tissue-engineered bioartificial implants sense and respond to inflammation in a feedback-controlled manner. (A to D) Genome-engineered stem cells on 
porous 3D woven scaffolds [(A) electron microscopy] were differentiated into chondrocyte-like cells that infiltrated the scaffold and filled the scaffold pores with cartilag-
inous matrix as shown by (B) confocal microscopy, (C) nano–computed tomography (nanoCT), (D) and Safranin O staining. (E) Ccl2-IL1Ra constructs produced IL-1Ra in 
response to IL-1 (n = 5 per time point) and (F) decreased IL-1Ra production rapidly after IL-1 withdrawal (n = 5 per day). (G) This response was repeatable over multiple 
cycles of iterative stimulation (n = 5 per group). (H to K) Ccl2–IL1Ra constructs (n = 6) mitigated mRNA levels for proinflammatory mediators as compared to Ccl2-Luc 
constructs (n = 5). Data in (E) and (G) were compared with two-way repeated measures ANOVA with Geisser-Greenhouse corrections and Sidak’s post hoc test, where 
significant adjusted P values per time point are illustrated in italics. Main effect P values are displayed for each graph. Data in (H) to (K) were evaluated using a two-way 
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drugs in a self-regulating manner. By engineering iPSCs to form a 
stable cartilaginous matrix, the implants exhibited extended viability 
and therapeutic function an in vivo model of RA, with the ability to 
serve as an autoregulated source for prescribed biologic drugs. The 
construct could be repeatedly reactivated by inflammatory chal-
lenges and showed superiority to standard-of-care treatment with 
conventional disease-modifying drugs and biologics. Furthermore, 
these implants can provide direct luminescence readouts of prepro-
grammed responses, opening up potential applications in real-time 
diagnostic assessment of the dynamic inflammatory environment.
While protein-based drug delivery, including enzyme-activated 
systems, have been successful in a number of applications (23–27), 
such approaches are generally based on repeated injections or on 
biodegradable materials and thus cannot easily supply continuously 
biologic molecules for long-term delivery, unlike the rapid dynamic 
stimulus-response functions that living cells can provide. In previ-
ous studies, “designer” or “smart” cell approaches have been used 
to develop cell therapies for metabolic diseases such as diabetes but 
have been based on transient transfection or viral gene delivery, 
resulting in unpredictable gene insertion sites or copy numbers (4). 
Fig. 4. Bioartificial implants demonstrate translationally relevant longevity, therapeutic efficacy, and retriggering dynamics. (A and B) When implanted in K/BxN 
model of RA, Ccl2-Luc implants expressed consistent luciferase and (C) photon flux was similar across subcutaneous implantation on the dorsal aspect or proximal to the 
knee joint in mice (n = 3 per group). (D) Explanted constructs demonstrated high cell viability via confocal microscopy. (E) Ccl2-Luc implants were delivered to mice and 
(F) challenged to evaluate the on-dynamics where significant increase in photon flux (photons per second) was observed 1 hour after K/BxN STA. (G) Luciferase signal was 
measured in concert to clinical score over an initial flare, and after a week-long washout period through which minimal signal was detected in concert with attenuated 
clinical score. The same mice were triggered with a second K/BxN STA flare where a proportional increase in signal was observed. (H and I) An additional group of mice 
were treated with therapeutic constructs, which laid dormant in mice for 30 days before K/BxN STA, at which time they successfully mitigated disease severity when 
compared to Ccl2-Luc constructs. (J) H&E and Safranin O/Fast Green staining of paraffin sections of scaffolds before implantation and after implantation, followed by 
immunohistochemistry for collagen I, IIa1, and X. n = 5 to 6 per group, two-way ANOVA with Geisser-Greenhouse corrections: different letters indicate P < 0.001 by Tukey’s 
post hoc test. (B) n = 3 to 8, one-way ANOVA; (F) n = 3 to 5 per group, two-way repeated measures ANOVA with Tukey’s post hoc test; (C, G, and I) two-way ANOVA: adjusted 
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This study is among the first to demonstrate use of CRISPR-Cas9 
gene editing for precise control of the stimulus-response locus 
in vivo (3), as well as the potential for tunability and genome editing 
of cytokine receptors for treating model systems of an inflammato-
ry condition (6, 28). Recent human studies have illustrated the util-
ity and feasibility of applying CRISPR-Cas9–edited cells in human 
patients, for example, in a clinical trial of edited autologous T cells 
that were found to safely and feasibly treat lung cancer (29). The 
next frontier of development for applying genome engineering to 
develop therapeutic cells is to apply tissue engineering in combina-
tion with these synthetic biology tools (30) to develop artificial gene 
circuits that can sense and respond dynamically to disease markers. 
The present approach may provide new opportunities for developing 
safe and effective therapies for a broad range of chronic diseases 
such as RA (31).
Cell-based therapies may provide the next frontier of medicine 
by providing systems that can be precisely engineered for highly 
controlled, long-term drug delivery (32). For example, patients with 
RA typically require frequent (weekly or biweekly to monthly) sys-
temic dosing of biologic regimens. Thus, a stable implantable drug 
delivery system could overcome the burden of repeated self-administered 
injections. This clinical need motivated the investigation of a 
longer-lasting implant seeded with genome-edited Ccl2-IL1Ra 
cells to deliver biologic therapeutic over a longer time frame. As the 
Fig. 5. Ccl2-IL1Ra bioartificial implants mitigate disease severity, inflammation, and pain in mice with K/BxN STA. (A to C) Ccl2-IL1Ra implants mitigated disease 
severity as measured by clinical scores and ankle thickness, in contrast to control groups (n = 20, 12, and 8, respectively). Two-way repeated measure ANOVA with Geisser- 
Greenhouse corrections was calculated, and main effects are displayed in each graph. Adjusted P values for Ccl2-IL1Ra versus Ccl2-Luc scaffolds are shown in italics 
near each time point. (D to F) At sacrifice, these implants reduced inflammation [(E), n = 8 and 9, left to right] and maintained cartilage integrity [(F), n = 7 per group]. 
Zoomed images are shown in the yellow boxes, and black arrows illustrate differential inflammatory cell infiltration and proteoglycan staining between treated and un-
treated groups. (G to J) IL-1Ra levels and ratio of IL-1:IL-1Ra in serum were increased in mice with Ccl2-IL1Ra implants compared to all other groups, and IL-1Ra concen-
tration in serum had negative relations with clinical scores and ankle thickness [(G), n = 10, 6, 12, and 8, left to right; (H), n = 10 per group]. (K to N) Mice that received 
Ccl2-IL1Ra implants maintained their pain thresholds, indicated by algometry and electronic Von Frey pain tests in contrast to all other groups and significantly related 
with IL-1Ra concentration in serum (n = 20, 12, and 8, respectively). All values represent means ± SEM. (B, C, K, and L) Two-way repeated measures ANOVA. (E and F) 











Choi et al., Sci. Adv. 2021; 7 : eabj1414     1 September 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
7 of 12
clinical course of RA is typically punctuated by flares alternating 
with remissions, an ideal therapeutic strategy should be responsive 
and effective in blunting the endogenous inflammatory challenges 
presented during flares. Using 3D woven scaffolds to engineer func-
tional cartilage implants (16), the Ccl2-driven bioengineered cells 
demonstrated feedback-controlled dynamics in response to fluctu-
ating levels of cytokines commonly implicated in arthritis, suggest-
ing that these bioartificial implants indeed could sense and respond 
to the in vivo environment perpetuated by K/BxN models of in-
flammatory arthritis. We also observed that the Ccl2-IL1Ra bio-
artificial implants could be triggered and retriggered to the same 
magnitude and the circuit was turned “off” when not stimulated, 
representing advantages that could mitigate adverse events associ-
ated with continuous protein administration (2). Given the harsh 
inflammatory environment in the K/BxN F1 mice, the finding that 
implants survived and functioned appropriately over 5 weeks in vivo 
suggests that this approach, with further optimization, could supplant 
the clinical need of frequent injections of biologic drugs in patients 
with RA. A limitation of the present study is the absence of longer 
time points beyond 40 days that will inform the translational poten-
tial of this approach. We are currently exploring the delivery of 
these constructs using other biomaterials that allow for encapsula-
tion of cells at higher densities and long-term survivability, which 
represent the critical next steps in the development of these Ccl2-IL-
1Ra and Ccl2-sTNFR1 for anticytokine therapies.
In addition to the significant ~40% reduction in the inflammatory 
index conferred by the Ccl2-IL1Ra implants, this approach resulted 
in complete mitigation of bone erosions. Bone erosions are fre-
quently observed in RA (33) and are associated with poor functional 
outcomes. However, most biologics currently available in the clinic 
rarely inhibit both inflammation and bone erosions (33). The ability 
to mitigate both inflammation and structural damage using this ap-
proach suggests that inhibition of IL-1 signaling in an autoregulated 
manner may provide added therapeutic advantage in the prevention 
of bone loss and joint destruction in inflammatory arthritis. Recently, 
a population of FAP+ THY1− fibroblasts that produce high levels of 
matrix metalloproteases (MMPs) have been shown to selectively me-
diate bony erosions in inflammatory arthritis (34). We demonstrated 
Fig. 6. Ccl2-IL1Ra bioartificial implants prevent bone damage and mitigate endogenous inflammation in mice with K/BxN STA. (A to E) Mice treated with Ccl2-IL-
1Ra implants demonstrated reduced bone damage by microCT as quantified by (B) BS/BV, (C) BV/TV, and (D) BMD (n = 10, 7, 12, and 7, left to right). (E). Significant rela-
tionships were observed between BS/BV and serum levels for IL-1Ra. (F to N) Mice receiving Ccl2-IL1Ra implants also showed less systemic (F to H) and local inflammation 
in lysate from a single hind paw (I to N) as compared to mice with Ccl2-Luc implants or no implants (n = 10 per group). All values represent the mean fold change in ex-
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Fig. 7. Ccl2-IL1Ra bioartificial implants demonstrate improved clinical efficacy over standard-of-care treatment. No significant therapeutic benefit was observed 
with (A) a single intraperitoneal injection of methotrexate (MTX × 1) on day 2 or three intraperitoneal injections of methotrexate (MTX × 3; on days 2, 4, and 6) or (B) tofacitinib 
twice daily starting on day 2 compared to phosphate-buffered saline (PBS) or vehicle controls. (C and D) Neither benchmark treatment resulted in a significant mitigation 
of ankle thickness, (D) hyperalgesia, (E) paw withdrawal, (F) Von Frey pain threshold (G) ratio of BS/BV, nor (H) BV/TV to the levels of healthy controls. (I) Ccl2-IL1Ra animals 
demonstrated significantly reduced clinical scores versus anakinra but (J) similar levels of circulating IL-1Ra when measured at day 7 at sacrifice (final dose was administered 
evening of day 6). (A, C, E, and F) Italicized P values indicate Tukey’s test for Ccl2-IL1Ra versus MTX1 or MTX3. (B and D) Ccl2-IL1Ra versus tofacitinib. (I) Ccl2-IL1Ra 
versus Anakinra at each time point. (J) P values indicate Ccl2-IL1Ra versus no treatment and no K/BxN. All values represent means ± SEM. (A to F) Two-way ANOVA with a 
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in vitro that Ccl2-IL1Ra cells blunted the production of MMP-13 in 
response to IL-1 challenge, suggesting that modulation of MMP 
expression underlies the mechanism by which IL-1 drives the ero-
sive disease in RA.
The bioartificial implants outperformed standard-of-care bench-
mark comparators evaluated in this context, including methotrexate 
and tofacitinib. Notably, Ccl2-IL1Ra implants outperformed anakinra, 
suggesting that cell-based release of therapeutic levels of IL-1Ra on 
demand in response to endogenous inflammatory signals provides 
a superior mode of delivery as compared to the standard exogenous 
delivery of anakinra (e.g., twice daily injections). This finding is 
consistent with previous studies that suggest that the short half-life 
and rapid clearance of IL-1Ra following injection may be responsible 
for the inconsistent clinical efficacy (35).
The present cell-based anticytokine therapy dynamically senses 
and responds to the environment, so this feature can help overcome 
the short half-life and rapid clearance, as IL-1Ra is being synthe-
sized continuously in response to stimulus, rather than being deliv-
ered in a single bolus that is rapidly cleared (36). Of note, the 
level of IL-1Ra in mice implanted with Ccl2-IL1Ra scaffolds and 
mice receiving anakinra was similarly low at sacrifice, day 7 in mice 
with scaffolds and ~20 hours after the last dose of anakinra. How-
ever, we reasoned that Ccl2-IL1Ra implants outperformed anakinra 
because of sustained levels of IL-1Ra released by the Ccl2-IL1Ra 
cells in direct response to stimulation by endogenous inflammatory 
mediators in the setting of K/BxN serum challenge. The short half-
life of anakinra is well known, and the rapid clearance of exogenous 
anakinra in mice has been documented (36). While the bulk of 
anakinra is cleared within hours following systemic administration 
in mice (36, 37), IL-1Ra released by a single challenge of IL-1 per-
sists for at least 72 hours (Fig. 3E). In addition, the response of Ccl2 
cells in the K/BxN STA model is sustained for days (Fig. 4G). Thus, 
the vastly different kinetics of endogenous IL-1Ra released by stim-
ulated Ccl2 cells and exogenously administered anakinra likely ex-
plain the differing efficacy between the two treatments. The in vitro 
data presented here demonstrate robust and consistent IL-1Ra pro-
tein concentrations through 24 hours after a single stimulus. This 
cell-based approach also includes the time required for protein syn-
thesis of IL-1Ra, as it is transcribed in the cell-based system rather 
than delivered as a functional protein, which we speculate that this 
transcription in response to inflammatory stimuli may help over-
come the short half-life and rapid clearance of injectable IL-1Ra. 
However, this hypothesis remains to be directly tested and is the 
focus of ongoing studies.
Another explanation for the lack of efficacy of clinical DMARDS 
in this model system may be due to both dosing and altered drug 
kinetics between IL1Ra in humans and mice may explain the lack 
of efficacy of standard-of-care drugs in the present studies. Differ-
ence in drug kinetics is most evident in methotrexate-treated mice 
where once a week dosing (standard for RA therapy) shows no ef-
fect but every other day dosing three times leads to some mitigation 
of disease. Tofacitinib, on the other hand, has been shown to be ef-
fective in murine collagen–induced arthritis, especially when given 
continuously via subcutaneous pump administration (38). Lack of 
efficacy in the K/BxN STA suggests differences in molecular drivers 
of inflammation between the two models. Because IL-1Ra is the first 
line of treatment for several additional autoinflammatory diseases 
(cryopyrin-associated autoinflammatory syndromes, TNF receptor– 
associated periodic syndrome, familial Mediterranean fever, etc.) 
(39), the stable implantable approach may be explored for better 
control of inflammatory flares in other chronic conditions as well. 
We recognize that systemic immune suppression is also a common-
ly reported limitation of biologic drugs for these indications (40, 41). 
Future work will also focus on detailing how the present bioartifi-
cial drug delivery system may affect the immune system.
In summary, this cell-based anticytokine therapy represents an 
advance in the development of therapies for RA. Ccl2-IL1Ra cells 
seeded on a 3D woven scaffold represent a bioartificial implant sys-
tem that can overcome many clinical limitations of existing treat-
ment strategies for arthritides. By leveraging the flexibility of iPSCs 
as a cell source, this approach can be readily expanded to generate 
therapeutic cells that could be broadly applied and differentiated 
into any cell type in the future, allowing for additional applications 
to address a variety of chronic diseases and tissue types where 
defined biologic targets have been identified. Ongoing work is 
interrogating other biomaterials and synthetic gene circuits for fur-
ther tuning of the cellular responses in other chronic inflammatory 
disease models. Longer-term studies will inform the utility of this 
approach to other types of arthritis now that proof of concept has 
been established.
MATERIALS AND METHODS
Cell culture and in vitro assays
Murine iPSCs were engineered to incorporate a synthetic gene cir-
cuit to drive the expression of either Il1rn or firefly luciferase (Luc) 
via the Ccl2 locus (3). These iPSCs were predifferentiated in micro-
mass with bone morphogenetic protein 4 (17), seeded onto 3D wo-
ven PCL scaffolds (1 × 106 cells per scaffold), and cultured for 
21 days in serum-free chondrogenic medium containing Dulbecco’s 
modified Eagle’s medium–high glucose, nonessential amino acids, 
2-mercaptoethanol, ITS+ premix (BD), penicillin-streptomycin (Gibco), 
l-ascorbic acid 2-phosphate (50 g/ml), l-proline (40 g/ml), trans-
forming growth factor–3 (10 ng/ml; R&D Systems), and 100 nM 
dexamethasone (17, 42) to make implantable cartilage constructs 
(16). Gene expression changes in response to inflammatory cytokines 
[IL-1 (1 ng/ml) or TNF- (20 ng/ml)] were measured via quanti-
tative polymerase chain reaction (17, 43), and protein levels of secreted 
murine IL-1Ra were measured via enzyme-linked immunosorbent 
assay (ELISA) (DuoSet, R&D Systems).
NanoCT imaging of bioartificial implants
Implants were fixed overnight in 2.5% glutaraldehyde and 2% para-
formaldehyde in 0.1 M cacodylate buffer with 2 mM CaCl2. Second-
ary fixation was performed using 1% OsO4 in 0.1 cacodylate buffer 
for 1 hour at room temperature. Excess fixative was washed using 
deionized water, and the samples were incubated in Lugol’s iodine for 
72 hours at room temperature to further enhance contrast. Samples 
were embedded in 2% agarose and imaged on a Zeiss Xradia Versa 
540 x-ray microscope using a 0.4× flat panel detector. Images were 
reconstructed and presented as shaded volume renderings.
In vivo luciferase assays
Ccl2-Luc constructs were implanted on the dorsal aspect of F1 K/
BxN mice, which spontaneously develop chronic arthritis, to allow 
for longitudinal bioluminescence imaging of luciferase activity of 
the scaffolds in vivo daily for 1 week, and weekly thereafter over a 
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constructs were challenged with K/BxN serum and imaged daily for 
7 days. In vivo bioluminescence imaging was performed on the days 
indicated on an IVIS Lumina (PerkinElmer, Waltham, MA, USA; 
Living Image 4.2; 1-min exposure; bin, 8; field of view, 12.5 cm; 
f/stop, 1; open filter). Hair was removed from the area before imaging. 
Mice were injected intraperitoneally with d-luciferin [150 mg/kg in 
phosphate-buffered saline (PBS); Gold Biotechnology, St. Louis, MO, 
USA] and imaged using isoflurane anesthesia (2% vaporized in O2). 
Total photon flux (photons per second) was measured from fixed 
regions of interest over the lower back of the mice where the scaffolds 
were implanted using Living Image 2.6.
Cell viability assays
Cell survival and apoptosis were assessed using the Live/Dead Cell 
Viability/Cytotoxicity Kit for mammalian cells (Invitrogen/Molecular 
Probes, Carlsbad, California, USA). Live cells were labeled with 
calcein AM, and dead cells were labeled with ethidium homodimer-1 
bound to DNA. Labeled constructs were imaged using confocal mi-
croscopy (LSM 880, Zeiss, Thornwood, NY, USA) (16). Live/dead 
expression was quantified in histogram statistics (ZEN blue edition, 
Zeiss) as the percentage of 488 channel signaling normalized by to-
tal signaling from both channels for a flattened z stack collected of 
the half-construct.
K/BxN model of inflammatory arthritis
Male K/BxN transgenic mice and female B6.I-Ag7 mice were inter-
crossed to generate F1 that spontaneously developed arthritis be-
ginning at about 4 weeks of age and lasting for >20 weeks (15). STA 
was induced in C57BL/6 male and female mice with 150 to 175 l of 
K/BxN serum delivered by retro-orbital injection (14, 15, 44). One 
week before STA, mice received either subcutaneous Ccl2-IL1Ra 
scaffold implants on the dorsum (n = 8 scaffolds, 8 animals, experi-
mental group), Ccl2-Luc scaffolds, or no treatment (control groups, 
n = 8 to 13). In separate groups of C57BL/6 mice, animals were induced 
with STA and received methotrexate intraperitoneally, tofacitinib by 
oral gavage, or appropriate controls. Disease activity (clinical score 
and ankle thickness) and pain sensitivity (algometry and electronic 
Von Frey) were assessed daily for 1 week. Mice were then sacrificed, 
and serum and hind paws were collected for analysis. All procedures 
were approved by the Institutional Animal Care and Use Commit-
tee at Washington University in St. Louis.
The clinical score was assessed on a scale of 0 to 3 (0, no swelling or 
erythema; 1, slight swelling or erythema; 2, moderate erythema and 
swelling in multiple digits or entire paw; and 3, pronounced erythema 
and swelling of entire paw; maximum total score of 12) (45). The 
change from baseline in ankle thickness was determined daily by dial 
calipers, and an average change in the ankle thickness was deter-
mined for each mouse from the two hind paw measurements.
Pain and behavioral testing
Animals were acclimatized to the behavioral testing room before 
assessment. Algometry was performed using a pressure-based anal-
gesimeter (SMALGO, Bioseb, Vitrolles, France) by applying a pro-
gressive force over the ankle joint, and the stimulation was increased 
until a reaction (shudder or vocalization) from the animal was ob-
tained. The maximum force was then automatically recorded, ana-
lyzed, and reported as pressure-pain hyperalgesia.
To determine tactile allodynia, electronic Von Frey paw assays 
were used. Mice were placed in acrylic cages (12 cm by 10 cm by 
17 cm high) with a wire grid floor 15 to 30 min before testing in a 
quiet room. During this adaptation period, the hind paws were 
stimulated two to three times. Before hind paw stimulation, the an-
imals were kept quiet, without exploratory movements or defecation, 
and not resting on their paws. In these experiments, a pressure meter 
that consisted of a handheld force transducer fitted with a 0.5-mm2 
polypropylene tip (electronic von Frey anesthesiometer, IITC Inc., 
Life Science Instruments, Woodland Hills, CA, USA) was used. A 
tip was applied against the central edge of the animal hind paw, and 
the intensity of the stimulus was automatically recorded when the 
paw was withdrawn. The stimulation of the paw was repeated until 
the animal presented two similar measurements.
Histological analysis
Paws were harvested on day 7 after serum transfer, fixed in 10% 
neutral buffered formalin for 48 hours, and stored in 70% ethanol, 
before decalcification in EDTA solution and processing for paraffin 
embedding. Sections (5 m) were stained with H&E or toluidine 
blue. Inflammatory cells infiltrating the synovial lining and the joint 
cavity were enumerated in 8 to 10 random fields per section using 
H&E images acquired at ×400 magnification. Proteoglycan loss in 
the cartilage was scored on toluidine blue–stained sections on a 
scale from 0 to 3, ranging from fully stained cartilage (score, 0) to 
fully destained cartilage (score, 3), as previously described (45). Scoring 
was performed by an observer blinded to the treatment.
Histology and immunohistochemistry of scaffold sections
Constructs were fixed in 4% paraformaldehyde, embedded in 
paraffin, and sectioned at thickness of 5 m. For histological assess-
ments, constructs were stained with Safranin O/Fast Green or H&E 
according to previous methods (17). Collagen I, II, and X were 
detected using immunohistochemistry. Paraffin sections of scaffold 
were rehydrated, washed, and incubated for 20 min at 37°C with 
proteinase K (10 g/ml; BioLabs, catalog no. P8102S) diluted in 
10 mM tris-HCl (pH 8.0) for antigen retrieval. The slides were then 
treated with 3% peroxidase H2O2 in methanol and blocked with 5% 
donkey serum for 1 hour at room temperature. Primary antibodies 
collagen 1 (Abcam, ab90395), IIa1 (University of Iowa, II-II6B3-s), 
and X (Sigma-Aldrich, C7974) were diluted in 1% bovine serum 
albumin (BSA) to a concentration of 1:800, 1:1, and 1:400, re-
spectively, and incubated overnight at 4°C. The secondary anti-
body, peroxidase-conjugated donkey anti- mouse immunoglobulin G 
(Jackson ImmunoResearch, catalog no. 715-035-150), was diluted 
1:500 in 1% BSA and incubated at room temperature for 1 hour. 
Slides were developed using the HistoMark Orange Peroxidase 
Substrate Kit (SeraCare, catalog no. 5510-0033), dehydrated, 
mounted, and imaged. Mouse paws were used as controls for posi-
tive staining.
Quantitation of IL-1Ra and proinflammatory mediators
Levels of IL-1Ra in serum and single hind paws were assessed by ELISA 
(Quantikine-IL1Ra, R&D Systems). Levels of paw and serum inflam-
matory mediators were evaluated using Luminex (Mouse High Sen-
sitivity T cell Discovery Array 18-Plex, Eve Technologies, Calgary, 
AB, Canada).
MicroCT analysis of bone erosion
To measure bone morphological changes, intact hind paws were 
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voxel resolution at 50 kV, 500 A, 980-ms integration time, 3 frame 
averaging, and 0.5-mm aluminum filter to reduce the effects of beam 
hardening. Images were reconstructed using NRecon software (with 
20% beam hardening correction and 15-ring artifact correction). 
Hydroxyapatite calibration phantoms were used to calibrate bone 
density values (in g/cm3). Parameters reported are as follows: BS/BV, 
bone fraction (BV/TV), and BMD (in g/cm3).
Benchmark studies
Methotrexate, the first-line DMARD, and tofacitinib and anakinra, 
two Food and Drug Administration–approved biologic drugs for 
RA, were administered in the K/BxN STA to further assess the ther-
apeutic efficacy of Ccl2-IL1Ra constructs compared to standard of 
care for clinical RA. First, we assessed therapeutic efficacy of tofaci-
tinib (5 mg/kg), a JAK–signal transducer and activator of transcription 
inhibitor, given twice daily by oral gavage starting on day 2. Control 
mice received a methylcellulose (0.5% methylcellulose and 0.023% 
Tween 20 in PBS) vehicle control by oral gavage. Tofacitinib citrate 
(PZ0017, Sigma-Aldrich, St. Louis, MO, USA) was prepared in di-
methyl sulfoxide (DMSO) and diluted 1:10 in the vehicle control 
to a final volume of 10% DMSO. Note that the standard dose of 
tofacitinib in the clinic is 5 mg taken orally twice a day. Methotrexate 
(2.5 mg/kg) was given as a single intraperitoneal injection on day 2 
or as multiple injections on days 2, 4, and 6. Controls received PBS 
intraperitoneally at the same schedule as methotrexate. Note that the 
standard dose of methotrexate is 25 mg taken orally once a week. 
Next, to compare cell-based drug delivery versus conventional con-
stitutive IL-1Ra delivery, anakinra (50 mg/kg) was administered twice 
daily via intraperitoneal injection and was compared against Ccl2- 
IL1Ra scaffold implants through day 6. Clinical scores, ankle thick-
ness, and microCT measurements were conducted as described 
above on day 7.
Statistical analysis
Sample size was determined on the basis of a mean clinical score of 
10 ± 2 for K/BxN control animals and six for IL-1Ra–treated animals. 
On the basis of an alpha of 0.05 and 80% statistical power (1 − ) a 
priori, a sample size of four animals per treatment group was need-
ed to observe this effect. Normality was assessed by group using a 
Shapiro-Wilk test. Brown-Forsyth test was conducted to evaluate equality 
of variances. Outcomes were evaluated by two-way Student’s t test; 
one-way Mann-Whitney U test or one-, two-, and three-way repeated 
measures; or three-way analysis of variance (ANOVA) with a Geisser- 
Greenhouse correction to account for sphericity. Tukey’s post hoc 
test or Sidak correction was used to assess differences between 
groups, treatments, scaffold types, time, or a combination of those 
factors. Pearson or Spearman correlations were calculated between 
serum levels of IL-1Ra and outcomes (P ≤ 0.05). Investigators were 
not blinded to the clinical score or ankle thickness measurements. 
All other assessments and analyses were performed blinded.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/ 
sciadv.abj1414
View/request a protocol for this paper from Bio-protocol.
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